Overview and Scope
Bi-specific MAbs or bispecific monoclonal antibodies refer to antibodies that have two binding sites and are designed to bind to two antigens that are either distinct or have two different epitopes. Monoclonal antibodies (MoAbs) do not have the clinical therapeutic effects of BsAbs, which have a wide range of applications for the treatment of different diseases as well as tumour immunotherapy.
Sizing and Forecast
The bi-specific mabs market size has grown rapidly in recent years. It will grow from $8.81 billion in 2023 to $10.25 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to increased healthcare expenditure, increased funding and government initiatives.
The bi-specific mabs market size is expected to see rapid growth in the next few years. It will grow to $16.9 billion in 2028 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to an increasing prevalence of cancer, an increasing aging population and an increase in the prevalence of chronic diseases. Major trends in the forecast period include focus on technological advancements, product innovation, focus on artificial intelligence, investment in targeted and combination therapy and strategic partnerships.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report
Segmentation & Regional Insights
The bi-specific mabs market covered in this report is segmented –
1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab
2) By Product Type: In Vivo, In Vitro
3) By Indication: Cancer, Haemophilia A, Ophthalmic
4) By End Use: Hospitals, Research Institutes, Other End-Users
Top 5 Major Players:
- F. Hoffmann-La Roche AG
- Amgen Inc
- Johnson & Johnson
- Innovent Biologics
- Sino Biological Inc
North America was the largest region in the bi-specific MAbS market in 2023. The regions covered in the bi-specific mabs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective than monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression. For instance, in 2023, according to the Cancer Facts & Figures 2023 report published by the American Cancer Society (ACS), a US-based voluntary health organization, there will be an estimated 609,820 cancer related deaths in the USA. Therefore, a rising number of chronic diseases, including cancer, is anticipated to propel the demand for bi-specific MAbs to treat these diseases effectively.
Key Industry Players
Major companies operating in the bi-specific mabs market report are F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Innovent Biologics, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, EpimAb Biotherapeutics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, Enteris BioPharma, BioMarin Pharmaceuticals, Parexel, Hikma Pharmaceuticals PLC, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa
The bi-specific mabs market report table of contents includes:
1. Executive Summary
2. Bi-Specific MAbS Market Characteristics
3. Bi-Specific MAbS Market Trends And Strategies
4. Bi-Specific MAbS Market – Macro Economic Scenario
5. Global Bi-Specific MAbS Market Size and Growth
….
32. Global Bi-Specific MAbS Market Competitive Benchmarking
33. Global Bi-Specific MAbS Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Bi-Specific MAbS Market
35. Bi-Specific MAbS Market Future Outlook and Potential Analysis
36. Appendix
List Of Tables:
Table 1: Global Historic Market Growth, 2018-2023, $ Billion
Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
Table 3: Global Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 4: Global Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Table 5: Global Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
….
Table 75: F. Hoffmann-La Roche AG Financial Performance
Table 76: Amgen Inc Financial Performance
Table 77: Johnson & Johnson Financial Performance
Table 78: Innovent Biologics Financial Performance
Table 79: Sino Biological Inc Financial Performance
Explore the trending research reports from TBRC:
https://goodprnews.com/video-telemedicine-market-size/
https://goodprnews.com/synthetic-food-market-share/
https://goodprnews.com/aviation-crew-management-system-market-share/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
